Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
07:30:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6,795.00 JPY | -1.21% |
|
-3.38% | -17.57% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 11,316B 72.73B 62.58B 58.73B 53.73B 100B 6,876B 101B 695B 271B 3,514B 273B 267B | P/E 2026 * |
22.4x | P/E 2027 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise Value | 10,406B 66.88B 57.55B 54B 49.41B 92.22B 6,323B 92.95B 639B 249B 3,231B 251B 246B | EV / Sales 2026 * |
7.5x | EV / Sales 2027 * | 6.65x |
| Free-Float |
38.12% | Yield 2026 * |
1.98% | Yield 2027 * | 2.26% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4519 | Delayed | |
Mexican S.E.
| 4519 N | End-of-day quote | |
|
OTC Markets
| CHGCF | Delayed | |
|
Börse Stuttgart
| CUP | Delayed | |
|
Tradegate
| CUP | Real-time | |
|
Boerse Muenchen
| CUP | Real-time | |
|
Deutsche Boerse AG
| CUP | Delayed |
Last Transcript : Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.21% | ||
| 1 week | -3.38% | ||
| Current month | -1.71% | ||
| 1 month | +1.72% | ||
| 3 months | -10.20% | ||
| 6 months | -30.36% | ||
| Current year | -17.57% |
| 1 week | 6,777 |  | 6,976 |
| 1 month | 6,578 | | 7,229 |
| Current year | 6,575 | | 10,700 |
| 1 year | 6,250 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 28/02/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 27/03/2024 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 29/02/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 27/03/2024 |
| Director/Board Member | 51 | 28/02/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.21% | -3.38% | +3.27% | +53.01% | 72.73B | |
| -1.37% | -2.71% | +53.82% | +104.73% | 1,034B | |
| -1.04% | +2.92% | +54.32% | +71.69% | 671B | |
| -1.26% | +0.56% | +20.62% | +75.85% | 460B | |
| -0.08% | -0.70% | +29.20% | +38.25% | 353B | |
| -1.20% | +5.03% | +25.06% | +45.97% | 309B | |
| -0.96% | +0.51% | -1.29% | +12.55% | 255B | |
| -1.27% | +1.50% | +56.70% | +72.79% | 240B | |
| -0.61% | +1.05% | -17.17% | -54.44% | 207B | |
| -0.46% | +3.48% | +33.67% | +100.57% | 188B | |
| Average | -0.96% | +1.05% | +25.82% | +52.10% | 378.95B | |
| Weighted average by Cap. | -1.06% | +1.01% | +35.86% | +66.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.92B 7.68B 7.2B 6.59B 12.3B 843B 12.4B 85.23B 33.19B 431B 33.51B 32.78B | 1,529B 9.83B 8.45B 7.93B 7.26B 13.55B 929B 13.66B 93.85B 36.55B 475B 36.9B 36.09B |
| Net income | 506B 3.25B 2.8B 2.63B 2.4B 4.49B 308B 4.52B 31.08B 12.1B 157B 12.22B 11.95B | 583B 3.75B 3.23B 3.03B 2.77B 5.17B 354B 5.21B 35.82B 13.95B 181B 14.08B 13.77B |
| Net Debt | -910B -5.85B -5.03B -4.72B -4.32B -8.07B -553B -8.13B -55.87B -21.76B -283B -21.97B -21.49B | -1,151B -7.4B -6.36B -5.97B -5.46B -10.2B -699B -10.28B -70.65B -27.51B -357B -27.78B -27.17B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | JP¥6,795.00 | -1.21% | 1,920,500 |
| 03/09/26 | JP¥6,878.00 | +0.67% | 2,283,900 |
| 02/09/26 | JP¥6,832.00 | -1.47% | 2,345,900 |
| 01/09/26 | JP¥6,934.00 | +0.30% | 1,623,100 |
| 31/08/26 | JP¥6,913.00 | -1.71% | 2,937,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
